SCHEMBL4810260

SCHEMBL4810260

COc1ccc(C(c2ccc(OC)cc2)n2nc(-c3ccsc3)c3c2-c2ccc(CNC(=O)CCl)cc2C3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.39
ALDH1A1 P00352 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HTT P42858 2/20 0.37
PTGES O14684 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
KDR P35968 1/20 0.35
LMNA P02545 3/20 0.35
POLB P06746 3/20 0.35
MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4816463 0.95 PTGES (0.37) CNR1ALDH1A1SMN1; SMN2HTTPTGES
SCHEMBL4808626 0.95 CNR1 (0.39) CNR1ALDH1A1PTGESHDAC3HDAC4
SCHEMBL4816274 0.90 PTGES (0.37) CNR1ALDH1A1PTGESHDAC3HDAC4
SCHEMBL4817848 0.88 LMNA (0.42) CNR1ALDH1A1SMN1; SMN2HTTKDR
SCHEMBL4814720 0.88 ALDH1A1 (0.39) ALDH1A1KDRLMNAPOLBMAPT
SCHEMBL4807491 0.87 LMNA (0.36) CNR1ALDH1A1SMN1; SMN2PTGESHDAC3
SCHEMBL4812159 0.85 LMNA (0.43) CNR1ALDH1A1SMN1; SMN2HTTPTGES
SCHEMBL4816371 0.85 MMP2 (0.40) ALDH1A1KDRLMNAPOLBMAPT
SCHEMBL4810667 0.84 LMNA (0.42) CNR1ALDH1A1SMN1; SMN2HTTPTGES
SCHEMBL4817479 0.84 KDR (0.40) KDRGPBAR1KLK1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740579-B1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBVIE INC (US) 2015-08-19 EP disclosed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 US disclosed
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors ABBVIE INC. 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors PRKDC, PRKACA, PIK3C3 CNR1 2896/4885ALDH1A1 3901/4885SMN1; SMN2 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.